Skip to main content

Table 1 Demographics and baseline characteristics

From: The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial

 

Treatment group

 

Severe COPD patients

n = 28

Healthy subjects*

n = 27

Male, n (%)

21 (75)

11 (41)

Age, years

65 (48-80)

31 (20-65)

BMI, kg/m2

26.5 (21-32)

23.1 (18-29)

FEV1, l

1.10 (0.5-1.9)

3.8 (2.3-5.9)

FEV1, % PN

37.5 (24-51)

103.3 (84-131)

VC, l

2.8 (1.2-5.2)

4.6 (3.5-6.6)

FVC, l

2.7 (1.1-4.9)

-

FEV1, % FVC

42.4 (27-60)

-

FEV1, % VC

41.6 (26-63)

83.1 (66-103)

Median time since diagnosis, years (range)

8.8 (1-37)

-

Median pack-years (range)

40 (10-64)

-

Smoking status

 

-

   Previous, n

16

-

   Habitual, n

22

-

Inhaled ICS at entry

  

   n

18

-

   μg/day

777 (160-1600)

-

  1. Data are mean (range) unless otherwise indicated. BMI = body mass index; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; ICS = inhaled corticosteroid; PN = predicted normal; VC = vital capacity. * Data not collected in healthy subjects on FVC, FEV1, time since diagnosis (not applicable [NA]), smoking (NA) and ICS (NA) at study entry.